Cell and Gene Therapy Global Market Opportunities And Strategies To 2035 Published — Analyzes Hospitals, Cancer Care Centers and Other End Users

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The cell and gene therapy market remains highly concentrated, with the 10 largest competitors accounting for 66.6% of the market in 2024

  60% confidence

• Historic market growth was supported by the shift toward personalized and precision medicine, expansion of clinical trials, strong therapeutic pipelines, rising healthcare expenditure and increased investment in pharmaceutical and biotechnology companies

  60% confidence

• Asia-Pacific is forecast to be the fastest-growing region through 2030, recording a CAGR of 27.5%

  60% confidence

• Gene therapy is forecast to be the fastest-growing product segment between 2025 and 2030, with a CAGR of 26.1%

  60% confidence

• Cancer care centers are forecast to be the fastest-growing end-user segment, expanding at a CAGR of 25% during 2025-2030

  60% confidence

• Potential barriers to future growth include shortages of skilled professionals, stringent regulatory requirements, trade disruption and tariffs

  60% confidence

• Future growth is expected to be driven by an aging global population, the rising prevalence of cancer, the increasing burden of chronic and genetic diseases, and continued investment in cell and gene therapy research, manufacturing and commercialization

  60% confidence

• The United States offers the largest country-level opportunity, with projected market gains of $11.67 billion

  60% confidence

• High treatment and development costs, combined with limited healthcare access in some markets, constrained wider adoption

  60% confidence

Data points we hold from this source